The ABT101-102 clinical trial was approved by the Ministry of Health and Welfare and will be conducted at multiple medical centers.

The ABT101-102 clinical trial is divided into two phases, Phase I and Phase II, to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of ABT101 in patients with HER2 Exon20 mutated non-small cell lung cancer (NSCLC) using the BOIN (Bayesian optimal interval design) method. NSCLC patients with HER2 Exon20 mutation, the safety, tolerability, pharmacokinetics and antitumor efficacy of ABT101.